Abstract
Cisplatin (DDP) is a potent chemotherapeutic agent whose clinical use is limited by nephrotoxicity, often leading to acute kidney injury (AKI). This study investigates the role of the Transient Receptor Potential Ankyrin-1 (TRPA1) ion channel in mediating DDP-induced AKI. Using both in vivo mouse models and in vitro HK-2 cell models, researchers found that TRPA1 activation promotes endoplasmic reticulum (ER) stress and mitochondrial damage. Specifically, TRPA1 facilitates calcium overload through mitochondria-associated endoplasmic reticulum membranes (MAMs), leading to mitochondrial dysfunction and apoptosis. Inhibition of TRPA1 with HC-030031 or targeting the tethering protein GRP75 significantly mitigated these effects, suggesting TRPA1 as a potential therapeutic target for preventing cisplatin-induced nephrotoxicity.
Introduction
Cisplatin remains a cornerstone of cancer treatment, yet its effectiveness is frequently compromised by its side effects, most notably acute kidney injury (AKI). Approximately 20–30% of patients undergoing cisplatin therapy experience significant renal impairment. While oxidative stress and apoptosis are known contributors, the precise molecular mechanisms coordinating organelle failure—specifically the crosstalk between the endoplasmic reticulum (ER) and mitochondria—have remained elusive.
This research focuses on the Transient Receptor Potential Ankyrin-1 (TRPA1), a non-selective cation channel. The study explores how TRPA1 acts as a molecular "bridge" that facilitates destructive signaling between the ER and mitochondria, ultimately leading to renal cell death.
Methods
The study utilized a dual-model approach to dissect the pathways involved:
- In Vivo Model: Male C57BL/6 mice were administered cisplatin to induce AKI. A subset of these mice was treated with the TRPA1 antagonist HC-030031 to evaluate its protective potential.
- In Vitro Model: Human renal tubular epithelial (HK-2) cells were used for detailed molecular analysis, including the use of TRPA1 agonists (AITC), ER stress inhibitors (4-PBA), and GRP75 inhibitors (MKT077).
Key experimental techniques included Transmission Electron Microscopy (TEM) to visualize Mitochondria-Associated Endoplasmic Reticulum Membranes (MAMs), Western blotting for protein expression, and flow cytometry to measure calcium concentrations and mitochondrial membrane potential.
Key Insights: The MAM and Calcium Overload
The study identifies the physical contact points between the ER and mitochondria, known as MAMs, as the primary site of damage. TRPA1 activation leads to an upregulation of GRP75, a protein that tethers the two organelles. This tethering facilitates a massive transfer of calcium from the ER directly into the mitochondria.
This calcium overload triggers a cascade of failure:
- Mitochondrial Dysfunction: Loss of membrane potential and decreased ATP production.
- Oxidative Stress: A significant spike in Reactive Oxygen Species (ROS).
- Dynamic Imbalance: A shift toward mitochondrial fission (fragmentation) mediated by increased p-DRP1 and MFF, and decreased fusion proteins like MFN1 and MFN2.
Results
The experimental results demonstrated that inhibiting TRPA1 provides robust protection against cisplatin-induced damage:
- Renal Function: In mice, HC-030031 significantly lowered serum creatinine (Scr) and blood urea nitrogen (BUN) levels ($P < 0.001$).
- Cellular Preservation: TEM imaging showed that TRPA1 inhibition prevented the mitochondrial swelling and ER expansion typically seen after cisplatin exposure.
- Apoptosis: TUNEL staining confirmed a drastic reduction in apoptotic cells in kidney tissues when TRPA1 was inhibited.
- Protein Regulation: TRPA1 inhibition successfully downregulated ER stress markers (GRP78, CHOP) and restored the balance of mitochondrial fusion/fission proteins.
Conclusion
The study establishes a clear TRPA1-ERS-Mitochondria axis in the pathogenesis of cisplatin-induced AKI. By regulating the MAM-mediated calcium flux, TRPA1 serves as a critical driver of organelle dysfunction and subsequent renal cell death. These findings highlight TRPA1 as a promising pharmacological target for "reno-protective" strategies, potentially allowing for more aggressive cisplatin dosing in cancer patients while minimizing the risk of life-threatening kidney injury.
Summary updated